Arvinas (ARVN) Capital Expenditures Growth (3y) (2020 - 2026)
Arvinas (ARVN) Capital Expenditures Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Arvinas | 529.92 Mn | -84.98 Mn | - | 5.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.73% |
| Dec 31, 2025 | -91.29% |
| Sep 30, 2025 | 35.72% |
| Jun 30, 2025 | 40.10% |
| Mar 31, 2025 | -42.46% |
| Dec 31, 2024 | -9.14% |
| Sep 30, 2024 | 35.72% |
| Jun 30, 2024 | 16.96% |
| Dec 31, 2023 | -73.90% |
| Sep 30, 2023 | 34.93% |
| Jun 30, 2023 | -30.97% |
| Mar 31, 2023 | -6.88% |
| Dec 31, 2022 | 63.91% |
| Sep 30, 2022 | -26.94% |
| Jun 30, 2022 | -73.21% |
| Mar 31, 2022 | 76.70% |
| Dec 31, 2021 | 29.96% |
| Sep 30, 2021 | -38.10% |
| Dec 31, 2020 | 77.08% |